Drug Trial Radar · NCT07029139
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Apr 1, 2027
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.
Conditions
- Primary Membranous Nephropathy
Interventions
JMT601 InjectionDrug
In accordance with the protocol
RituximabDrug
In accordance with the protocol
Cyclosporin CapsulesDrug
In accordance with the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events in Part 1Time frame: Up to 24 weeks
- Overall Remission Rate at week 52 in Part 2Time frame: week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.